File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: Current trend of breast cancer therapeutics from the U.S. clinical trial database

TitleCurrent trend of breast cancer therapeutics from the U.S. clinical trial database
Authors
Issue Date2009
PublisherAmerican Society of Clinical Oncology
Citation
The 45th Annual Meeting of the American Society of Clinical Oncology (ASCO 2009), Orlando, FL., 29 May-2 June 2009. In Journal of Clinical Oncology, 2009, v. 27 n. 15S, abstract no. e17546 How to Cite?
AbstractBackground: The standard of breast cancer care has been based on clinical trial results. With the International Committee of Medical Journal Editors (ICMJE) requiring all clinical trials registered in a public trial registry as a condition of publication, the US trials registry "ClinicalTrials.gov" has become a global registry of currently available clinical trials. We aim to explore the current clinical trials to study the trend of breast cancer therapeutics development based on analysis of a comprehensive breast cancer trial database. Methods: We performed a systematic review of all breast cancer therapeutic clinical trials. All data were captured from ClinicalTrials.gov for all "industry-sponsored" phase I-IV trials in October, 2007 including trials that were first registered between October 2005 and September 2007. Essential data was extracted by a tailor-made Statistical Analysis System Program developed by Professor JP Karlberg at the University of Hong Kong. The data included register identity, study phase, study compounds and recruitment status etc. Results: Altogether 443 clinical therapeutic interventional trials were identified and classified into 10 modes of action. The latest five mostly studied compounds accounted for 32.73% of all the therapeutic trials (n = 145). Lapatinib, a dual kinase inhibitor is studied most in 31 trials (9 monotherapy). Docetaxel, a mitotic inhibitor is studied in 27 trials (10 monotherapy) while letrozole, an aromatase inhibitor, currently used in adjuvant setting is tested in 18 out of a total 22 trials as monotherapy. Antimetabolites such as gemcitabine being involved in 24 trials (2 monotherapy) with capecitabine studied in 21 trials (11 monotherapy), were followed by bevacizumab, a VEGF monoclonal antibody which is currently studied in 20 trials, and tested as combinations in 75% of the related trials. Conclusions: According to the US trial registry, current most commonly tested compounds for breast cancer include lapatinib, followed by docetaxel, gemcitabine, letrozole, and capecitabine. There is increasing new therapeutics with combination strategy. This supports the trend of personalized medicine in the management of breast cancer which is a heterogeneous disease.
Persistent Identifierhttp://hdl.handle.net/10722/61488
ISSN
2015 Impact Factor: 20.982
2015 SCImago Journal Rankings: 9.204

 

DC FieldValueLanguage
dc.contributor.authorKwok, SSen_HK
dc.contributor.authorTsang, JWHen_HK
dc.contributor.authorKarlberg, JPEen_HK
dc.date.accessioned2010-07-13T03:40:45Z-
dc.date.available2010-07-13T03:40:45Z-
dc.date.issued2009en_HK
dc.identifier.citationThe 45th Annual Meeting of the American Society of Clinical Oncology (ASCO 2009), Orlando, FL., 29 May-2 June 2009. In Journal of Clinical Oncology, 2009, v. 27 n. 15S, abstract no. e17546-
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/61488-
dc.description.abstractBackground: The standard of breast cancer care has been based on clinical trial results. With the International Committee of Medical Journal Editors (ICMJE) requiring all clinical trials registered in a public trial registry as a condition of publication, the US trials registry "ClinicalTrials.gov" has become a global registry of currently available clinical trials. We aim to explore the current clinical trials to study the trend of breast cancer therapeutics development based on analysis of a comprehensive breast cancer trial database. Methods: We performed a systematic review of all breast cancer therapeutic clinical trials. All data were captured from ClinicalTrials.gov for all "industry-sponsored" phase I-IV trials in October, 2007 including trials that were first registered between October 2005 and September 2007. Essential data was extracted by a tailor-made Statistical Analysis System Program developed by Professor JP Karlberg at the University of Hong Kong. The data included register identity, study phase, study compounds and recruitment status etc. Results: Altogether 443 clinical therapeutic interventional trials were identified and classified into 10 modes of action. The latest five mostly studied compounds accounted for 32.73% of all the therapeutic trials (n = 145). Lapatinib, a dual kinase inhibitor is studied most in 31 trials (9 monotherapy). Docetaxel, a mitotic inhibitor is studied in 27 trials (10 monotherapy) while letrozole, an aromatase inhibitor, currently used in adjuvant setting is tested in 18 out of a total 22 trials as monotherapy. Antimetabolites such as gemcitabine being involved in 24 trials (2 monotherapy) with capecitabine studied in 21 trials (11 monotherapy), were followed by bevacizumab, a VEGF monoclonal antibody which is currently studied in 20 trials, and tested as combinations in 75% of the related trials. Conclusions: According to the US trial registry, current most commonly tested compounds for breast cancer include lapatinib, followed by docetaxel, gemcitabine, letrozole, and capecitabine. There is increasing new therapeutics with combination strategy. This supports the trend of personalized medicine in the management of breast cancer which is a heterogeneous disease.-
dc.languageengen_HK
dc.publisherAmerican Society of Clinical Oncology-
dc.relation.ispartofJournal of Clinical Oncology-
dc.titleCurrent trend of breast cancer therapeutics from the U.S. clinical trial databaseen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailKwok, SL: sharonslkwok@yahoo.comen_HK
dc.identifier.emailTsang, JWH: jwhtsang@hkucc.hku.hken_HK
dc.identifier.emailKarlberg, JPE: jpekarl@hkucc.hku.hken_HK
dc.identifier.authorityTsang, JWH=rp00278en_HK
dc.identifier.authorityKarlberg, JPE=rp00400en_HK
dc.identifier.hkuros154605en_HK
dc.identifier.volume27-
dc.identifier.issue15S-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats